A Decade of Data: JCO PO and the TAPUR Study
From JCO Precision Oncology Conversations · 33:21
Show by American Society of Clinical Oncology (ASCO)
JCO PO Editor-in-Chief Emeritus Dr. James Ford and Founding PI, ASCO TAPUR Study, Dr. Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study and its relationship with the journal. Host Dr. Rafeh Naqash and guests discuss the inception/history of the TAPUR study, its future, and advances in precision medicine over the past decade. LINK TO FULL TRANSCRIPT
More episodes of JCO Precision Oncology Conversations
More episodes
- Pancreatic Imaging Findings in BRCA1/BRCA2/ATM/PALB2 Carriers
- Assessment of 2022 CMMRD Diagnostic Criteria
- EPCAM Deletion Architecture Defines Distinct Cancer Phenotype
- JCO PO Article Insights: Tumor-informed ctDNA in Early Triple Negative Breast Cancer
- EMR-Based Nudge Improves Molecular Testing in Early-Stage NSCLC
- JCO PO Article Insights: CTCs as Biomarkers in GBM
- Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford
- Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger
- Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan
- Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.